At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol Z1K: Ipatasertib in Patients With Tumors With AKT Mutations
In Brief
A Phase 2 clinical trial evaluating Biopsy Procedure, Biospecimen Collection, and 3 other interventions for Advanced Lymphoma and 4 related conditions. Active but no longer recruiting, targeting 35 participants across 1 site.
Signals
Detailed Summary
This phase II MATCH treatment trial tests how well ipatasertib works in treating patients with cancer that has certain genetic changes called AKT mutations. Ipatasertib is in a class of medications called protein kinase B (AKT) inhibitors. It may stop the growth of cancer cells and may kill them.
Study Details
Timeline
Arms & Interventions
Patients receive ipatasertib 400 mg PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo CT or MRI during screening and on study, as well as during follow-up as clinically necessary. Patients undergo biopsies and blood sample collection on study.
Interventions
Undergo biopsy
Undergo blood sample collection
Undergo CT scan
Given PO
Undergo MRI